Abstract
Background: Numerous diseases associated with COVID-19 infection and vaccination have been reported, including conditions such as the autoimmune blistering diseases (AIBDs) pemphigus and pemphigoid. However, robust evidence supporting these associations is lacking. Objective: To investigate the risk of developing AIBD following COVID-19 infection and vaccination. Methods: Population-based retrospective cohort study utilizing data from over 112 million patients. The risk of AIBD within 3 months was compared among 3 cohorts: COVID-19 infection, COVID-19 vaccination, and controls, along with 7 sensitivity analyses. Results: COVID-19 infection was associated with an increased risk of AIBD (hazard ratio [HR] 1.508, 95% CI 1.260-1.805), with the risk being more pronounced for pemphigus (HR 2.432, 1.618-3.657) compared to bullous pemphigoid (HR 1.376, 1.019-1.857). Conversely, COVID-19 vaccination was associated with an almost halved risk of AIBD (HR 0.514, 0.394-0.672), with the risk reduction most significant for pemphigus (HR 0.477, 0.241-0.946). Comparisons between COVID-19 infection and vaccination revealed a more than threefold increased risk of AIBD in the infection cohort (HR 3.130, 2.411-4.063), particularly for pemphigus (HR 5.508, 2.973-10.205). Limitations: Retrospective design and potential under-reporting of COVID-19 cases and vaccinations. Conclusion: COVID-19 infection significantly increases the risk of AIBD while vaccination appears to reduce this risk.
Original language | English |
---|---|
Journal | Journal of the American Academy of Dermatology |
Volume | 92 |
Issue number | 3 |
Pages (from-to) | 452-463 |
Number of pages | 12 |
ISSN | 0190-9622 |
DOIs | |
Publication status | Published - 03.2025 |
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)
- Centers: Center for Research on Inflammation of the Skin (CRIS)
DFG Research Classification Scheme
- 2.21-05 Immunology
- 2.22-19 Dermatology
Coronavirus related work
- Research on SARS-CoV-2 / COVID-19